Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

While maintaining its revenue forecast of $58 billion to $61 billion, the company expects EPS of $20.78 and $22.28, down from $22.50 to $24 per share. ... Eli Lilly's stock isn't cheap.

Eli Lilly (NYSE: LLY) sells a broad ... After all, from today's $28 billion market, the forecast figure represents a 239% increase. ... Before you buy stock in Eli Lilly, consider this: ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. The company's GLP-1 ...

With 12-month upside of 30-50% in a base-bull case, not buying Eli Lilly stock now is foolish. If you let the risks deter you, that's a lack of bravery, not a sign of intelligence.

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year. The ...

On this episode of Stock Movers: - Eli Lilly (LLY) shares fell the most intraday since October after CVS Health announced a plan to drop its blockbuster weight-loss drug Zepbound from its ...